Enhancing RNA encapsulation quantification in lipid nanoparticles: Sustainable alternatives to Triton X-100 in the RiboGreen assay
To quantify concentration and encapsulation efficiency (EE) of mRNA in lipid nanoparticles (LNPs) the RiboGreen assay is extensively used. As part of this assay, a surfactant is used to release mRNA from LNPs for detection with the RiboGreen dye. So far, the surfactant of choice has been Triton X-100, which is harmful to human health and the environment. Alternatives to Triton X-100 are therefore needed, but surprisingly no such effort has yet been described in the literature. Here we show how three, less harmful, surfactants (Brij 93, Zwittergent 3-14 and Tween 20) compare to Triton X-100 for releasing mRNA from LNPs for detection with the RiboGreen assay. We found that Zwittergent 3-14 and Tween 20 at high concentrations (0.5 %) are at the minimum as effective as Triton X-100 at high concentration (0.5 %) across three different mRNA-LNP formulations. Interestingly, Tween 20 was the most effective at releasing mRNA from LNPs, across all concentration ranges explored (0.0025 %, 0.01 %, 0.1 % and to 0.5 % (v/v)) highlighting its potency at solubilizing the three different LNP formulations. Our results show that Tween 20 can be used as an alternative to Triton X-100 in the RiboGreen assay, resulting in more accurate quantification of the total mRNA concentration and EE%, as well as making the assay more environmentally friendly. Such improvement could potentially increase the likelihood of identifying therapeutically attractive hard-to-solubilize LNP-mRNA formulations that would be discharged when using Triton X-100 due to their apparent low EE values, as well as ensure more accurate mRNA dosing in both in vitro and in vivo studies.
Authors
- Jens B. Simonsen (ORCID: https://orcid.org/0000-0002-4797-8570)
- Thomas L. Andresen (ORCID: https://orcid.org/0000-0002-1048-127X)
- David P. Schultz (ORCID: https://orcid.org/0009-0005-3380-9863)
- Nadin Jahnke (ORCID: https://orcid.org/0009-0000-0184-1168)
- Paul J. Kempen (ORCID: https://orcid.org/0000-0003-2179-2257)
- André M. Cantin (ORCID: https://orcid.org/0000-0001-7889-2094)
- Rasmus Münter (ORCID: https://orcid.org/0000-0001-5595-9540)
- Andrew J. Urquhart (ORCID: https://orcid.org/0000-0002-5322-0002)
Institutions
- Novo Nordisk (Denmark) (DK)
- TrygFonden (DK)
- Technical University of Denmark (DK)
Publication Details
- Journal
- European Journal of Pharmaceutics and Biopharmaceutics
- Published
- 2024-10-28
- DOI
- https://doi.org/10.1016/j.ejpb.2024.114571
- Citations
- 12
- Primary Topic
- RNA Interference and Gene Delivery
- Type
- article
- Field-Weighted Citation Impact
- 2.81
Funders
- Lundbeckfonden
- Novo Nordisk Fonden